Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: the head-to-head randomized controlled InRange trial - Battelino, T; Danne, T; Edelman, S V (Diabetes Obes Metab, 2023)